What Is BPC-157? A Research Guide

TL;DR: BPC-157 (“Body Protection Compound-157”) is a synthetic, stabilized pentadecapeptide — 15 amino acids — whose sequence is derived from a protective protein found in human gastric juice. Preclinical and animal research has examined it for effects on tissue repair, angiogenesis (new blood-vessel formation), and the gut-brain axis. It is not an FDA-approved drug, and in 2023 the FDA declined to add it to the 503A list of bulk drug substances eligible for use in compounded medications — which is part of why it is distributed for laboratory research use rather than through pharmacies. For laboratory research use only; not for human consumption.

What BPC-157 Is

BPC-157 is a research peptide consisting of a chain of 15 amino acids (a pentadecapeptide). The “BPC” stands for Body Protection Compound — the peptide’s sequence corresponds to a fragment of a larger protective protein originally identified in gastric juice. Unlike many natural peptide fragments, BPC-157 was engineered to be unusually stable in solution, which made it a practical subject for laboratory study. Approximate molecular details (molecular weight, CAS identifier) are listed on the BPC-157 product page and on the COA that ships with each order — researchers should use the COA’s net peptide content for any quantitative work.

Studied Mechanisms (Preclinical)

Across cell-culture and rodent models, published research has examined several proposed mechanisms for BPC-157:

• Angiogenesis — promotion of new blood-vessel formation, with some studies pointing to involvement of VEGFR2 signaling and the nitric-oxide (NO) pathway.
• Growth-factor and cytoskeletal signaling — interactions reported with growth-factor receptors and pathways relevant to cell migration and tissue remodeling.
• Gut-brain axis — research has explored BPC-157 in models of gastrointestinal injury and its interactions with dopaminergic and serotonergic systems.
• Cytoprotection — protective effects in various organ-injury models in animals.

These findings come overwhelmingly from preclinical work — in vitro and in animal models. BPC-157 has not gone through the human drug-approval process, and the body of controlled human data is limited. Descriptions of its effects should stay qualitative and model-specific.

What Preclinical Research Has Examined

Rodent studies have looked at BPC-157 in injury models spanning tendon, ligament, muscle, bone, nerve, and the gastrointestinal tract, generally reporting accelerated repair-associated outcomes relative to controls in those specific models. Other lines of work have examined effects on blood-vessel formation, on the gut-brain axis after gastrointestinal insult, and on protection of organs under various stressors. Again — these are research observations in defined experimental systems, not clinical conclusions.

Safety and Side Effects

The most important fact about BPC-157 safety is also the simplest: it has not been established. BPC-157 is a research compound, not an approved drug, and it has not completed the controlled human trials that would generate a recognized safety and side-effect profile. Almost everything written below comes from preclinical work — cell-culture and rodent studies — which does not transfer directly to humans. Wikipedia’s BPC-157 article summarizes the same point: as of its current revision, there are no published clinical trials demonstrating BPC-157’s safety or efficacy in humans.

What are the side effects / risks of BPC-157?

There is no characterized human side-effect profile for BPC-157, because the controlled human studies that would produce one have not been done. Rodent toxicology in the published literature has generally reported BPC-157 as well tolerated at the doses tested, with reviews by Sikiric and colleagues noting an absence of observed toxic effects in those specific animal models (review on PMC). That is a meaningful research observation — but it is not the same as a demonstrated human safety margin, and it says nothing about long-term use, drug interactions, or effects in people with existing conditions.

Three points researchers should keep in view:

• Animal-model tolerability is not a human safety claim. Doses, exposure windows, and endpoints in rodent studies were chosen for research questions, not to model human use.
• Sourcing variability is a real risk factor. Because BPC-157 is sold through research-chemical channels rather than pharmacies, identity, purity, and net peptide content vary between vendors. A third-party COA establishing what is actually in the vial is the only objective check — see how to read a peptide COA.
• Unknowns dominate. Long-term exposure, carcinogenicity, reproductive effects, and immune response in humans are simply unstudied. “No reported effect” in a short rodent study is not evidence of “no effect.”

BPC-157 is for laboratory research use only and is not intended for human consumption.

Is BPC-157 hard on kidneys?

There is no clinical evidence that BPC-157 is either harmful or protective to human kidneys — the question has not been studied in people. The reason it comes up at all is that preclinical research points in the opposite direction: several rodent studies have examined BPC-157 in models of kidney injury and reported cytoprotective, repair-associated outcomes in those specific models, consistent with the broader “body protection compound” line of research (organ-protection review on PMC).

That preclinical signal should be read carefully. It does not establish that BPC-157 is safe for human kidneys, and it does not establish a kidney risk either — it means the only data available are animal studies in deliberately induced injury models. Anyone framing BPC-157 as “kidney-safe” or “kidney-damaging” for humans is going beyond what the published evidence supports.

What should you not mix BPC-157 with?

Honestly: BPC-157 drug-interaction data in humans does not exist, so there is no validated list of things it is unsafe to combine with. Interaction profiles come from clinical pharmacology studies, and those have not been run for BPC-157.

What the research literature does show is the experimental pairings researchers commonly study — most notably TB-500 (thymosin beta-4), examined alongside BPC-157 in tissue-repair work because the two are proposed to act through largely non-overlapping mechanisms (the informal “Wolverine combination,” covered in BPC-157 vs TB-500). That is a research design choice, not a safety endorsement of co-administration. The accurate statement is the conservative one: because no human interaction data exists, no combination — with other peptides, supplements, or pharmaceuticals — can be assumed safe. This is research-context information, not guidance for use in humans.

BPC-157 vs TB-500 (Short Version)

BPC-157 is often studied alongside TB-500, a synthetic peptide related to thymosin beta-4. The two are proposed to act through largely non-overlapping mechanisms — BPC-157 with an angiogenesis / growth-factor emphasis, TB-500 with an actin-regulation / cell-migration emphasis — which is why researchers frequently examine them together (the informal “Wolverine combination,” also stocked as the Wolverine stack). For the full comparison, see BPC-157 vs TB-500.

Reconstitution Reference for Research

Standard lyophilized-peptide handling applies:

• Store the lyophilized powder at -20°C or below, desiccated and away from light.
• Let a cold vial reach room temperature before opening (prevents condensation).
• Reconstitute with bacteriostatic water, directing the stream along the inside wall of the vial — not onto the powder. Let it dissolve undisturbed; do not shake or vortex.
• Refrigerate the reconstituted stock at 2–8°C, protect from light, and use within roughly 30 days; aliquot and freeze if longer storage is needed.

Use the Peptide Reconstitution Calculator for concentration math, and see the full reconstitution guide and storage & stability guide. This is lab-prep reference information, not a dosing protocol.

Regulatory Status

BPC-157 is not a controlled substance and not an FDA-approved drug. In 2023 the FDA determined that BPC-157 should not be placed on the 503A list of bulk drug substances eligible for use in compounded drugs, citing insufficient safety information for compounding. That regulatory posture is why BPC-157 is sold through research-chemical channels with research-use-only labeling rather than through pharmacies. For more on the legal landscape, see Are Research Peptides Legal?.

Frequently Asked Questions

What does BPC-157 stand for?

“Body Protection Compound-157.” The sequence corresponds to a fragment of a protective protein originally identified in gastric juice.

How big is the BPC-157 peptide?

It’s a pentadecapeptide — 15 amino acids. Approximate molecular weight and CAS number are on the product page and the COA.

What have preclinical studies examined?

Effects on tissue repair (tendon, ligament, muscle, bone, GI tract in rodent models), angiogenesis, growth-factor and nitric-oxide signaling, and the gut-brain axis — in cell-culture and animal systems.

Is BPC-157 FDA-approved?

No. It’s not an approved drug, and the FDA declined in 2023 to add it to the 503A compounding bulks list. It’s sold for laboratory research use only.

How is BPC-157 different from TB-500?

BPC-157 is a synthetic pentadecapeptide derived from a gastric-juice protein, studied around angiogenesis and growth-factor signaling. TB-500 relates to thymosin beta-4 and is studied around actin regulation and cell migration. See BPC-157 vs TB-500.

How do I reconstitute BPC-157 for research?

Reconstitute with bacteriostatic water along the vial wall, let it dissolve without shaking, refrigerate the stock, and use within about 30 days. See the reconstitution guide and the calculator.

What are the side effects / risks of BPC-157?

There is no characterized human side-effect profile, because controlled human trials have not been done. Rodent toxicology studies have generally reported it as well tolerated at the doses tested, but that is an animal-model observation — not a demonstrated human safety margin. Long-term effects, drug interactions, and effects in people with existing conditions are unstudied.

Is BPC-157 hard on kidneys?

There is no clinical evidence either way — it has not been studied in human kidneys. Some rodent studies have examined BPC-157 in induced kidney-injury models and reported cytoprotective outcomes, but that preclinical signal does not establish human kidney safety or kidney risk.

What should you not mix BPC-157 with?

No human drug-interaction data exists for BPC-157, so there is no validated list of unsafe combinations. Researchers do study it alongside TB-500 in tissue-repair work, but that is an experimental design choice, not a safety endorsement of co-administration.

Does Elyte Peptides provide a COA for BPC-157?

Yes — a third-party COA ships with every order. See the product page and FAQ.

References

• Sikiric, P., et al. Reviews and primary studies on BPC-157 preclinical pharmacology (angiogenesis, NO pathway, gut-brain axis, organ protection, tissue repair) — PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7445278/
• Chang, C.H., et al. Studies on BPC-157 and tendon/ligament repair in animal models — PubMed.
• “BPC-157” — Wikipedia: https://en.wikipedia.org/wiki/BPC-157 (notes the absence of published human clinical trials).
• PubChem entry for BPC-157 — pubchem.ncbi.nlm.nih.gov.
• FDA, “List of Bulk Drug Substances for Use in Compounding Under Section 503A” and the 2023 determination on BPC-157 — Federal Register / fda.gov.

---

All products sold by Elyte Peptides are for laboratory research use only. Not for human consumption. Not FDA-approved. These statements have not been evaluated by the Food and Drug Administration.